StreetInsider.com News Articles

Form 4 Kiniksa Pharmaceuticals For: Aug 19 Filed by: Quart Barry D

Fri, 21 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260821/26961884.html

Form 4 Kiniksa Pharmaceuticals For: Aug 19 Filed by: Quart Barry D

Fri, 21 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260821/26961884.html

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

Fri, 07 Aug 2026 16:01:00 -0400

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46^th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

Fri, 07 Aug 2026 16:01:00 -0400

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives

Form 4 Kiniksa Pharmaceuticals For: Aug 01 Filed by: Levy Richard S

Tue, 04 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260804/26867289.html

Form 4 Kiniksa Pharmaceuticals For: Aug 01 Filed by: Levy Richard S

Tue, 04 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260804/26867289.html

Form 4 Kiniksa Pharmaceuticals For: Jul 29 Filed by: Cole G Bradley

Fri, 31 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260731/26851268.html

Form 4 Kiniksa Pharmaceuticals For: Jul 29 Filed by: Cole G Bradley

Fri, 31 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260731/26851268.html

Kiniksa (KNSA) PT Raised to $90 at Goldman Sachs

Thu, 30 Jul 2026 06:39:00 -0400

Goldman Sachs analyst Paul Choi raised the price target on Kiniksa (NASDAQ: KNSA) to $90.00 (from $75.00) while maintaining a Buy rating.

Form 144 Kiniksa Pharmaceuticals Filed by: Tessari Eben

Wed, 29 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260729/26834781.html

Form 144 Kiniksa Pharmaceuticals Filed by: Tessari Eben

Wed, 29 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260729/26834781.html

Form 144 Kiniksa Pharmaceuticals Filed by: Cole G Bradley

Wed, 29 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26834747.html

Form 144 Kiniksa Pharmaceuticals Filed by: Cole G Bradley

Wed, 29 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26834747.html

Form SCHEDULE 13G Kiniksa Pharmaceuticals Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:20:00 -0400

si-local-file:///var/storage/secattach/20260729/26834285.html

Form SCHEDULE 13G Kiniksa Pharmaceuticals Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:20:00 -0400

si-local-file:///var/storage/secattach/20260729/26834285.html

Kiniksa (KNSA) PT Raised to $107 at JPMorgan

Wed, 29 Jul 2026 08:50:18 -0400

JPMorgan analyst Anupam Rama raised the price target on Kiniksa (NASDAQ: KNSA) to $107.00 (from $72.00) while maintaining a Overweight rating.

Kiniksa (KNSA) PT Raised to $87 at Wells Fargo

Wed, 29 Jul 2026 08:13:38 -0400

Wells Fargo analyst Eva Fortea Verdejo raised the price target on Kiniksa (NASDAQ: KNSA) to $87.00 (from $74.00) while maintaining a Overweight rating.

Kiniksa (KNSA) PT Raised to $98 at Canaccord

Wed, 29 Jul 2026 06:43:00 -0400

Canaccord analyst Edward Nash raised the price target on Kiniksa (NASDAQ: KNSA) to $98.00 (from $64.00) while maintaining a Buy rating.

Form 10-Q Kiniksa Pharmaceuticals For: Jun 30

Tue, 28 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260728/26827386.html

Form 10-Q Kiniksa Pharmaceuticals For: Jun 30

Tue, 28 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260728/26827386.html

Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q2 EPS by 1c ; Offers Guidance

Tue, 28 Jul 2026 07:56:32 -0400

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.30, $0.01 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $243.6 million versus the consensus estimate of $226.56 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2026 revenue of $980-995 million, versus the consensus of $940.1 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q2 EPS by 1c ; Offers Guidance

Tue, 28 Jul 2026 07:56:32 -0400

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2026 revenue of $980-995 million, versus the consensus of $940.1 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

Form 8-K Kiniksa Pharmaceuticals For: Jul 28

Tue, 28 Jul 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260728/26822438.html

Form 8-K Kiniksa Pharmaceuticals For: Jul 28

Tue, 28 Jul 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260728/26822438.html

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Tue, 28 Jul 2026 07:30:00 -0400

– ARCALYST^¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –
– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –
– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –
– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –
– Conference call and webcast scheduled for 8:30 am ET today –

LONDON, July 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals